Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Aeolus Pharmaceuticals Inc (EM) AOLS

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:AOLS)

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESS Newswire July 31, 2023

Aeolus Announces Commencement of Assignment for the Benefit of Creditors

ACCESS Newswire March 23, 2018

Aeolus Announces Presentation of Pharmacometric Analysis Confirming Statistically Significant Improvement in Survival 6 Months After Exposure to Lethal Thoracic Radiation Following Treatment with AEOL 10150

ACCESS Newswire September 26, 2017

Aeolus Announces Presentation of Pharmacometric Analysis of Data Establishing Optimal Dose Schedule of AEOL 10150 for Treatment of Lung Radiation Damage

ACCESS Newswire September 22, 2017

Aeolus Announces Publication of Data Demonstrating that Adding AEOL 10150 to Standard Therapy After Nerve Agent Exposure Improves Survival and Reduces Brain Damage and Nerve Inflammation in Rats

ACCESS Newswire September 20, 2017

AEOLUS' AEOL 10150 is Safe and Well Tolerated in Phase 1 Study in Healthy Subjects

ACCESS Newswire September 18, 2017

Aeolus Announces Third Quarter Financial Results for Fiscal Year 2017

ACCESS Newswire August 14, 2017

Aeolus Announces FDA Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event

Marketwired June 8, 2017

Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017

Marketwired May 15, 2017
View More News ››

Opinion & Analysis (EXPM:AOLS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:AOLS)

Looks promising

I believe this one is an undiscovered gem...hopefully they'll be some more talk about this one soon
BullLogic2k6 - February 24, 2006
View more Bullboard ››

Allied Critical Metals Inc.

Allied Critical Metals Inc.

Allied Critical Metals (ACM:CSE) is a Canadian-based mining company focused on the expansion and revitalization of its 100 ...
View More »